IDEAYA and Roche Collaboration | Lucid Diligence Brief

IDEAYA announced on 03 Jun 2026 a clinical collaboration with Roche to test IDE892, an MTA-cooperative PRMT5 inhibitor, with Roche’s RG6505 pan-RAS inhibitor in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma, with IDEAYA sponsoring the study and Roche supplying RG6505. (IDEAYA press release, PR Newswire release)

Roche’s pipeline page, last updated 23 Apr 2026, lists RG6505 as a pan-RAS inhibitor in solid tumors, while ClinicalTrials.gov lists IDE892 as a multicenter study in MTAP-deleted advanced solid tumors. (Roche pipeline, ClinicalTrials.gov IDE892 trial record)

60-second thesis frame

The diligence hinge is whether synthetic-lethal MTAP targeting can convert from elegant biology into tolerable combination efficacy in a hard tumor where RAS-mutant disease is common and standard outcomes remain poor. IDEAYA frames MTAP deletion as occurring in up to 40% of PDAC, but other public scientific materials cite lower ranges, including more than 20% and around 30%, so patient-finding assumptions should be haircut until assay, prevalence, and eligibility are shown in the actual protocol. (IDEAYA press release, ASCO abstract, BostonGene publication) The upside case is a rational doublet, PRMT5 plus pan-RAS, with optional future triplet potential using IDE397. The risk case is that Phase 1-on-Phase 1 stacking creates overlapping toxicity, slow enrollment, and ambiguous contribution of components.

The seven diligence questions

Clinical

• What starting dose and escalation logic protect the therapeutic window when a PRMT5 inhibitor is layered onto a pan-RAS inhibitor, rather than tested sequentially after monotherapy dose maturity?
• Does the protocol pre-specify MTAP homozygous deletion, RAS mutation class, prior lines, and PDAC histology tightly enough to avoid a noisy basket signal?

Payer or Access

• Will a future payer case require broad tumor NGS plus MTAP copy-loss confirmation, and who pays for reflex testing in community PDAC pathways where deterioration is rapid?
• How will access be framed if daraxonrasib or another RAS-directed therapy reaches the market first in previously treated metastatic PDAC? FDA permitted expanded access for daraxonrasib in May 2026, but that is not the same as approval. (FDA expanded access announcement)

Ops or Adoption

• Can IDEAYA and Roche recruit fast enough in a molecularly sliced PDAC segment, especially if patients must have documented MTAP deletion and a RAS mutation before clinical decline?

Competitive

• Is the combination differentiated from broader RAS inhibitors, mutant-selective KRAS programs, MAT2A combinations, and other MTA-cooperative PRMT5 inhibitors, or is it mainly a biology claim until response depth and duration emerge? (Reuters daraxonrasib coverage, IDEAYA IDE892 Phase 1 update, MarketScreener collaboration summary)

Team or Cap table

• Does the structure, IDEAYA sponsor, Roche supply, each retaining commercial rights, create enough governance speed if the doublet works, or does it leave future development economics unresolved? (IDEAYA press release)

Red flags

• The MTAP prevalence signal is not uniform across sources, IDEAYA cites up to 40% in PDAC, while other public scientific materials cite more than 20% or about 30%, so market-sizing should not use the highest figure without protocol-level assay assumptions. (IDEAYA press release, ASCO abstract, BostonGene publication)
• The doublet is clinically early on both sides, Roche lists RG6505 in development and IDE892 is in Phase 1, so preclinical synergy may not translate into tolerable human exposure. (Roche pipeline, ClinicalTrials.gov IDE892 trial record)
• A faster-moving pan-RAS agent in PDAC could reset the benchmark before IDE892 plus RG6505 has interpretable efficacy data. FDA expanded-access action for daraxonrasib shows the competitive clock is active. (FDA expanded access announcement, Reuters daraxonrasib coverage)

Next catalyst

Watch for the first posted protocol amendment or trial record update adding the IDE892 plus RG6505 PDAC cohort, followed by initial Phase 1 safety, PK, and early response disclosures. IDEAYA said it plans Phase 1 combination cohorts in PDAC with RG6505 and in NSCLC and other solid tumors with IDE397. (IDEAYA press release, IDEAYA IDE892 Phase 1 update)

FAQ

What exactly changed by IDEAYA’s “clinical collaboration with Roche in MTAP-deleted RAS-mutant pancreatic cancer” news on 03 Jun 2026, and why does it matter for PDAC?

IDEAYA and Roche agreed to evaluate IDE892 plus RG6505 in MTAP-deleted, RAS-mutant PDAC, with IDEAYA sponsoring the study and Roche supplying RG6505. (IDEAYA press release) It matters because the combination tests two linked hypotheses, MTAP synthetic lethality through PRMT5 inhibition and broader RAS pathway blockade in a tumor where RAS alterations are central.

What is the regulatory path after IDEAYA’s 03 Jun 2026 collaboration announcement?

This is not a registrational announcement, it is an early clinical collaboration around Phase 1 assets. IDEAYA’s public release points to planned Phase 1 combination cohorts, while Roche’s pipeline lists RG6505 as a pan-RAS inhibitor in solid tumors. (IDEAYA press release, Roche pipeline) The next formal proof point is protocol visibility and early human safety, not an FDA or EMA filing.

Which endpoints should investors care about after the IDEAYA and Roche announcement on 03 Jun 2026?

The first endpoint is tolerability at biologically relevant exposure, because combination dosing can fail before efficacy is tested. Early efficacy should focus on confirmed response rate, duration of response, progression-free survival, and whether MTAP/RAS biomarker strictness enriches signal rather than shrinking enrollment too far.

What safety issues matter post-announcement, and could they change real-world use?

The core safety question is whether PRMT5 inhibition and pan-RAS inhibition create overlapping cytopenia, GI, dermatologic, or hepatic liabilities that force dose reductions. Since both agents are early, diligence should demand exposure-response, discontinuation rates, and dose-intensity data before assigning commercial probability.

How might payers treat access if IDE892 plus RG6505 ultimately advances?

Payers would likely require molecular confirmation of MTAP deletion and RAS mutation, probably through NGS or validated copy-loss testing. The access case may also depend on how pan-RAS competitors evolve, because FDA’s May 2026 expanded-access action for daraxonrasib signals a changing PDAC benchmark even before formal approval. (FDA expanded access announcement)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 04 Jun 2026, 06:53 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

IDEAYA Biosciences; Roche; Genentech; IDE892; RG6505; RO7673396; IDE397; PRMT5; MTA-cooperative PRMT5 inhibitor; pan-RAS inhibitor; MAT2A inhibitor; MTAP deletion; RAS mutation; KRAS; pancreatic ductal adenocarcinoma; PDAC; solid tumors; synthetic lethality; Phase 1; ClinicalTrials.gov; NCT07277413; daraxonrasib; RMC-6236; FDA; expanded access; ASCO; payer access; NGS testing; companion diagnostics; molecular selection; oncology combinations; biomarker enrichment; dose escalation; dose expansion; safety; PK; pharmacodynamics; response rate; progression-free survival; duration of response; US; EU; UK